Skip to content

Author

Guodong Yu

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Jul 2026

Plasticizers and prostate cancer: unraveling the link through network toxicology and machine learning

Background Plasticizers, as widespread environmental endocrine disruptors, are increasingly linked to an elevated risk of prostate cancer (PCa). However, the specific molecular mechanisms by which they drive PCa initiation and progression remain incompletely elucidated. Addressing this knowledge gap is crucial for assessing environmental health risks and identifying potential intervention targets. Methods This study employed a multi-level integrated research strategy. First, the toxicological profiles of target plasticizers were predicted using ADMETlab and ProTox platforms. Second, plasticizer-related targets were identified by integrating multiple databases and then cross-referenced with differentially expressed genes in PCa from TCGA and GEO cohorts to obtain shared targets. Subsequently, a protein-protein interaction (PPI) network was constructed and analyzed topologically. GO and KEGG enrichment analyses were performed to explore underlying biological processes and pathways. A total of 98 combination prediction models based on 10 machine learning algorithms were developed and evaluated to identify core prognostic genes. Furthermore, single-cell and spatial transcriptomics data were utilized to examine the expression localization of core genes within the tumor microenvironment. Molecular docking simulations were conducted to validate the binding affinity between plasticizers and core target proteins. Finally, in vitro experiments demonstrated the pro-tumorigenic effects of DMP and its regulatory role in PLK1 expression in prostate cancer cells. Results Toxicity predictions confirmed the carcinogenic potential of DEP, DMP, and DOP. A total of 183 bridging genes connecting plasticizers and PCa were identified. Enrichment analysis revealed their significant involvement in key pathways including inflammatory response, cell cycle, p53 signaling, and chemical carcinogenesis. PPI network analysis preliminarily screened hub genes such as ALB and MMP9. Through systematic machine learning modeling and prognostic analysis, the core targets were further narrowed down to PLK1, ALB, and CCNA2. Among these, high expression of PLK1 was significantly associated with shorter disease-free survival in multiple independent cohorts. Molecular docking results indicated that all three plasticizers could bind stably to the PLK1 protein with high affinity (binding free energy < -5.0 kcal/mol). Single-cell and spatial transcriptomic analyses showed high expression of PLK1 in tumor epithelial cells. In vitro experiments confirmed that DMP promotes the proliferation, migration, and invasion of PCa cells, as well as upregulates PLK1 expression. Pan-cancer analysis further indicated that PLK1 is commonly overexpressed in various cancers and associated with poor prognosis. Conclusion This study integrates computational toxicology, bioinformatics, machine learning, and experimental validation to reveal that common plasticizer exposure may promote PCa progression through dysregulation of cell cycle and inflammatory pathways, with PLK1 identified as a central molecular target. These findings establish a multi-omics evidence chain supporting the carcinogenic potential of environmental endocrine disruptors and provide a scientific basis for considering PLK1 as both a biomarker for risk assessment and a therapeutic target in plasticizer-associated PCa.

Yiting Jiang, Jian Shi, Shiwang Yuan et al. · 0 citations
Open access Aug 2026

Metformin improves chronic rhinosinusitis with depressive-like behavior in mice by targeting TCF4 to inhibit the TLR4/NF-κB pathway

Chronic rhinosinusitis (CRS) frequently co-occurs with depressive disorders. TCF4 aberrant expression is strongly linked to CRS with depression-like behaviors (CRSDB), highlighting the urgent need for TCF4-targeted drugs to treat this complex comorbidity. This study validated the reproducibility and stability of the previously developed mouse model of CRSDB by assessing nasal and hippocampal histopathology via H&E, PAS, and Nissl staining. ELISA determined inflammatory cytokine levels. TCF4’s role was explored through lentivirus-mediated in vivo and in vitro microglial knockdown. TLR4/NF-κB pathway regulation by TCF4 was confirmed via immunofluorescence, Western Blot, and RT-qPCR. Metformin’s therapeutic effect was tested, with its TCF4 targeting verified by molecular docking and in vitro experiments. The study comprehensively links TCF4 to neuroinflammation in CRSDB, highlighting metformin’s potential as a therapeutic agent. The CRSDB model exhibited excellent reproducibility and time-dependent exacerbation of depression-like behaviors, cognitive deficits, and concurrent nasal and hippocampal inflammation. Mechanistically, CRSDB induced TCF4 upregulation, which activated the TLR4/NF-κB signaling pathway, leading to microglial activation and neuroinflammation. Knockdown of TCF4 significantly alleviated behavioral impairments, suppressed microglial activation, and mitigated peripheral inflammation. Furthermore, We identified TCF4 as a direct target of metformin, through which it inhibits the TLR4/NF-κB pathway and subsequent microglial activation. TCF4 has been confirmed as a key regulatory mediator of CRSDB, and it has been demonstrated that metformin exerts its antidepressant effect by specifically targeting TCF4 in microglia to inhibit the TLR4/NF-κB axis.

Bingxi Yu, Fandong Yang, Jingwen Tian et al. · 0 citations